Work

Re-engineering Alzheimer Clinical Trials: Global Alzheimer’s Platform Network

Year: 2016

Type: article

Source: The Journal of Prevention of Alzheimer s Disease

DOI: 10.14283/jpad.2016.93

Authors: J. Cummings, P. Aisen, R. Barton, J. Bork, R. Doody, J. Dwyer, J. C. Egan, H. Feldman, D. Lappin, L. Truyen, S. Salloway, R. Sperling, G. Vradenburg

Institutions: Cleveland Clinic, Lou Ruvo Brain Institute, University of Southern California, Eli Lilly (United States), Baylor College of Medicine, Global Alzheimer's Platform Foundation, University of British Columbia, Johnson & Johnson (United States), Brown University, Harvard University

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Alzheimer's Association, Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Biogen, Teva Pharmaceutical Industries, Eisai, Kyowa Hakko Kirin, H. Lundbeck A/S, National Institutes of Health, Genentech, University of California, San Diego, Avid Radiopharmaceuticals, National Institute on Aging, National Institute of General Medical Sciences

Awards: G104586243, G1129981694, G1880935189, G2889627318, A Phase 2 Trial of AAV-NGF Gene Delivery in Alzheimer's Disease, G3146424788, G3553156159, G3870774570, Alzheimer's Disease Cooperative Study (ADCS), G5209990037, Alzheimer's Disease Neuroimaging Initiative, G6371410416, G6899163935, VITAMIN E TRIAL IN PERSONS WITH DOWN SYNDROME, G781725486, G9000039018, G9000122335, G9000239186, Renewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - Resubmission

OpenAlex ID: W2975397257

FWCI: 7.516

Cites: 25

Cited by: 55

Related to: 10